Review Article
Fueling chimeric antigen receptor T cells with cytokines

Jin Jin[1,2], Jiali Cheng[1,2], Meijuan Huang[1,2], Hui Luo[1,2], Jianfeng Zhou[1,2]

[1]Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China; [2]Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, Hubei, China

Abstract: Chimeric antigen receptor (CAR)-T therapy started a new era of tumor treatment, especially for hematological malignancies. However, many challenges remain, including low-level proliferation and short-term persistence, insufficient CAR T-cell trafficking, suppressive tumor microenvironment (TME), frequent adverse events and the unaffordable manufacturing process. Cytokines are pleiotropic hormones involved in multiple processes of immunity, including activation, expansion, differentiation, and migration of immune cells. Both pre-clinical models and clinical trials showed that armoring CAR-T cells with cytokines strengthened the anti-tumor responses of CAR T cells. This review looked into the key role of cytokines as a promoter of anti-tumor activities of CAR-T cells and consequently a facilitator of clinical translation, mainly, from cytokines of the common γ-chains family, chemokines and chemokine receptors, immunosuppressive molecules and pro-inflammatory cytokines.

Keywords: Chimeric antigen receptor T cells, cytokines, persistence, tumor microenvironment, endogenous immunity

Introduction

Immunotherapy represents an unprecedented breakthrough in the field of cancer treatment [1], and treatment with anti-CD19 chimeric antigen receptor (CAR)-T cells achieved over 90% complete remission [2-6]. However, many challenges remain, including ineffectiveness in solid tumors due to poor expansion, insufficient trafficking and immunosuppressive microenvironment [7], high recurrence rates [5, 8] and frequent adverse events [9], as well as staggering treatment cost [10], etc. Additional strategies are urgently required to optimize CAR-T therapy, including expanding its application, attaining longer-term efficacy and reducing side effects.

Cytokines are pleiotropic hormones, including interleukins (ILs), tumor necrosis factors (TNFs), interferons (IFNs), chemokines, colony-stimulating factors (CSFs), growth factors, among others. They are involved in the activation, proliferation, differentiation, and survival of various immune cells [11]. Due to their ability to regulate immune functions, combine use of CAR-T cells and cytokines could achieve a synergistic effect, which has shown great promise for cancer treatment. This review looked into the application of cytokines in CAR-T treatment from four aspects, i.e., cytokines of the common γ-chains family, chemokines and chemokine receptors, immunosuppressive molecules and pro-inflammatory cytokines.

Cytokines of the common γ-chains family

Proliferation, survival and persistence are the premises for CAR T-cell cytotoxic function to achieve cancer clearance and durable remission. Multiple clinical trials demonstrated that robust expansion [8] and long-time persistence [12] of CAR-T cells resulted in enhanced clinical responses and prolonged survival, while poor *in vivo* proliferation was closely correlated with relapse after transient remissions [13]. Here, we principally discuss the role of common γ-chains (γc)-sharing cytokines in proliferation, survival and persistence of CAR-T cells, *ex vivo* and *in vivo* (**Table 1**).

Ex vivo culture and exogenous administration

Interleukin (IL)-2 is most frequently used for *in vitro* T-cell expansion because of its pivotal role

Table 1. Summary of improving CAR-T efficacy through cytokines of the common γ-chain family

Related cytokines	Application	Mechanism	Diseases	Clinical trials	References
IL-2	Ex vivo culture and administration	Promote T cells expansion	B cell malignancies	NCT00924326	[16-19]
		Promote Treg cells expansion	Ovarian Cancer	NCT00019136	
		AICD	Metastatic Melanoma	NCT04119024	
				NCT03098355	
IL-15, IL-7, IL-21	Ex vivo culture	Preserve memory-enriched phenotype	B cell malignancies	NCT02992834	[21-24]
				NCT02652910	
				NCT04186520	
IL-15	Co-expression	Promote T cells expansion and persistence	B cell malignancies	NCT03721068	[28-31]
		Preserve Tscm phenotype	Glioblastoma		
			Neuroblastoma		
	MbIL15	Preserve Tscm phenotype	B cell malignancies	NCT03579888	[32]
		Continuously activate JAK/STAT5 pathway			
IL-7	IL-7Rα (with exogenous IL-7)	Selective promote CAR-T proliferation	EBV+ lymphoblastoma	-	[34, 35]
			Neuroblastoma		
	C7R	Continuously activate JAK/STAT5 pathway	Metastatic neuroblastoma	NCT04099797	[36, 37]
		Independent on soluble cytokines	Orthotopic glioblastoma	NCT03635632	
			Triple-negative breast cancer		
IL-23	IL-12β p40 subunit (p40-Td cells)	Induce Th17 phenotype	Neuroblastoma	-	[40]
		Autocrine mechanism	Pancreatic cancer		
γc cytokines	28-ΔIL2RBz (YXXQ) CAR-T	Activate JAK/STAT3 and STAT5	B cell malignancies	-	[38]
		In an antigen-dependent manner			

Clinical trial-related information were mainly collected from ClinicalTrials.gov. Abbreviations: CAR, chimeric antigen receptor; IL, interleukin; Treg, regulatory T cells; AICD, activation-induced cell death; Tscm, stem cells memory T; MbIL15, membrane-bound IL-15; EBV, Epstein-Barr virus; JAK/STAT5, Janus kinase/signal transducer and activator of transcription 5; C7R, constitutively active IL-7 cytokine receptor; Th, helper T cells.

Figure 1. Mechanisms to improve efficacy of CAR-T therapy through cytokines of the common γ-chain family. CAR-T cells co-expressing γc-sharing cytokines (IL-7, IL-15), or directly activating related STAT3 and/or STAT5 pathways (mbIL15, C7R, γc cytokines), exhibit enhanced expansion and persistence. IL-23 does not belong to the common γc family, but it also promotes the proliferation and persistence of lymphocytes through activating STAT3 pathway.

in lymphocyte growth and differentiation, and it is known to promote the expansion of cytotoxic T lymphocytes (CTLs) and the development of terminally-differentiated effector T (Te) cells. However, researches indicated that IL-2 simultaneously elicited clonal growth of regulatory T cells (Treg) [14] and the excessive levels of IL-2 induce apoptosis of Te cells, dubbed activation-induced cell death (AICD) [15]. In addition, a study demonstrated that lower levels of IL-2 worked better on T-cell expansion [16].

Moreover, exogenous administration of cytokines for functional modulation of CAR-T cells also improves the efficacy of immunotherapy [17]. IL-2, as the only γc cytokines approved by FDA, has been extensively investigated in combination with CAR-T therapy for intravenous or subcutaneous administration to treat cancers in initial clinical trials (NCT00924326, NCT00019136, NCT04119024, NCT030983-55), and was found to able to promote the expansion of adoptive immune cells *in vivo*

[18]. However, the high-dose IL-2 might have systemic toxicity [19]. Subsequently, studies suggested that appropriately reducing the dose of IL-2 [16] and intermittent administration [20] could balance the anti-tumor effects and systemic toxicity.

In fact, apart from IL-2, other cytokines of the common γc family also exhibited essential and distinct functions related to the proliferation, differentiation and persistence of T cells [14]. IL-7, IL-15 and IL-21 facilitated the production of "younger" memory-like lymphocytes such as central memory T (Tcm) cells and stem cells memory T (Tscm) cells, which persisted longer and possessed durable anti-tumor activities *in vivo* [21-25]. What's more, IL-15-mediated CAR-T cells reduced the activation of mTORC1, which held more advantages in survival in the TME [26]. Many pertinent clinical trials aimed to compare IL-2 pre-treated CAR-T cells and IL-7/IL-15 pre-treated CAR-T cells in terms of the safety, efficacy and duration of responses in patients with relapsed and refractory (r/r) CD19+ B cell lymphoma have been registered (NCT02992834, NCT0-2652910, NCT04186520).

Co-expression in CAR-T cells

In addition to expanding CAR-T cells with supplementing cytokines, expressing favorable cytokines on CAR-T cells also improved proliferation and persistence *in vivo*, and induced less systemic toxicities compared with exogenous administration (**Figure 1**).

IL-15: Unlike IL-2, activated T cells cannot produce IL-15 [27], which prompted researchers to treat tumors by generating CAR-T cells armed with IL-15. Compared with traditional adoptive therapy, IL-15-secreting CAR-T cells could downregulate the expression of programmed cell death protein 1 (PD1) and achieved 3- to

15-fold more expansion [28], with a higher proportion of Tscm cells in B-cell malignancies, glioblastoma [29] and neuroblastoma [30]. Subsequently, the clinical trial on IL-15-secreting CAR-T cells for r/r neuroblastoma has been registered (NCT03721068). Another study showed that CAR-T cells introduced both IL-15 and IL-21 rather than either of them was capable of enhancing proliferation with more Tscm and Tcm cells populations in hepatocellular carcinoma (HCC) [31].

Membrane-bound IL-15 (mbIL15), in which, as its name implies, IL-15 is directly bound with IL-15Rα, was able to continuously phosphorylate the signal transducer and activator of transcription (STAT) 5 pathway and yielded pro-survival signals all times. The novel CAR-T cells co-expressing mbIL15 developed long-term persistence independent of CAR signaling [32]. Based on this, Partow Kebriaei et al initiated a clinical research (NCT03579888) to ascertain the efficacy and safety of CAR-T cells incorporating mbIL15.

IL-7: IL-7 is also a decisive lymphocyte survival factor [14]. Different from IL-2, Treg cells have no IL-7Rα [33]. Thus, exogenously administered IL-7 could selectively stimulate CAR-T cell proliferation even in the context of fully functional Tregs [34, 35]. Thomas Shum et al proposed a novel constitutively active IL-7 cytokine receptor (C7R) [36], which significantly activated STAT5 through IL-7Rα homodimerization independent of cytokine administration or secretion. In many xenograft models [36, 37], less doses of C7R.CAR-T cells persisted longer and exerted more remarkable anticancer properties compared with conventional CAR-T therapy. Subsequently, the same team has also applied for initiation of new clinical trials (NCT04099797, NCT03635632).

γc cytokines: Common γc-sharing cytokines play a critical role in T-cell growth. IL-2, IL-7 and IL-15 tend to induce STAT5 activation, whereas IL-21 preferentially activates STAT3 to stimulate T-cell proliferation [14]. A study innovatively incorporated a truncated IL-2R β-chain (IL-2Rβ) as well as a STAT3 binding motif (YXXQ) into CD19 CAR-T cells. This new-generation CAR-T cells could activate both Janus kinase (JAK)/STAT3 and STAT5 when antigen-stimulated rather than constitutively activated, which had superior expansion, persistence, anti-tumor

activities and less side effects such as systemic toxicity [38].

IL-23: IL-23 does not belong to the common γc family, but it also promotes the proliferation and persistence of lymphocytes through activating STAT3 pathway [39]. The IL-23 is composed of two subunits: p19 and p40 [39]. Of interest, T cells increased the expression of p19 subunit without the p40 subunit after TCR engagement. On the basis of this discovery, Xingcong Ma et al generated a new CAR-T structure expressing the p40 subunit so that it could form IL-23 upon stimulation, thus facilitating expansion and persistence via autocrine IL-23 signaling without bystander effects in neuroblastoma and pancreatic cancer models [40].

Chemokines and chemokine receptors

To exert their cytotoxic effects, immune cells need to localize at tumor sites. Also, a high density of tumor-infiltrating lymphocytes (TILs) is strongly related to a favorable prognosis of most carcinomas [41]. However, chemokines secreted by tumor cells in the TME "mismatch" the endogenous chemokine receptors expressed on T cells, which poses a dominant obstacle of localization at tumor sites [42]. Therefore, co-expressing appropriate chemokine receptors on CAR-T cells and regulating chemokines secreted by tumors promote the trafficking and infiltration of adoptive immune cells into the tumor bed, thereby enhancing anti-tumor effects (**Figure 2**; **Table 2**).

CCR4/CCR2b

Different tumor malignancies possess distinctly different chemokine profiles. Reed-Stemberg cells in Hodgkin lymphoma (HL) tend to secrete C-C chemokine ligand (CCL) 17 and CCL22, recruiting C-C chemokine receptor (CCR) 4-positive Th2 and Treg cells to form immunosuppressive TME [43, 44]. CD30 CAR-T cells incorporating CCR4 could enhance migration to HL cells, exerting robust anti-tumor effects [45]. Later, clinical trials were initiated to ascertain the effectiveness of CCR4.CAR-T cells in cancer patients (NCT03602157, NCT04153799). Similarly, in neuroblastoma [46] and mesotheliomas [47], CAR-T cells transferring CCR2b also drastically increased TILs by 12.5-fold with enhanced cytotoxic activity.

Figure 2. Workflow of using chemokines and chemokine receptors to facilitate CAR T-cell migration and infiltration. On the basis of the chemokines secreted by tumor cells, CAR-T cells are armored with "matched" cytokine receptors including CCR4, CCR2b, CXCR1 and CXCR2 to enhance migration to the tumor bed. Besides, drugs such as SX-682 is able to block the trafficking of CXCR2+ MDSC by downregulating the expression of CXCR1 and CXCR2. Other drugs such as sitagliptin and docetaxel can increase the secretion of CXCL10 and CXCL11 in the TME, respectively, and combine use with CAR-T therapy also dramatically improve the density of TILs. Additionally, CCL19-secreting CAR-T cells can recruit adoptive and endogenous immune cells (T cells and DCs), and further enhance the anti-tumor effects of CAR-T therapy together with aforementioned IL-7.

CXCL10/CXCL11

In addition to working on chemokine receptors, fine-tuning ligands expressed by tumors is also a theoretically sensible approach. *In vivo*, C-X-C chemokine ligand (CXCL) 10, CXCL11 and their receptor CXCR3 are vital chemokine pairs that modulate endogenous lymphocyte migration. Anne-Marie Lambeir *et al* demonstrated that dipeptidyl peptidase IV (DPP4 or CD26) is capable of truncating CXCL10 to impair its function [51]. In fact, DPP4 inhibitor, Sitagliptin, coupled with immunotherapy, could enhance the migration of endogenous and adoptive lymphocytes, and producing synergistic anti-tumor effects in animal models [52]. Similarly, docetaxel increases the secretion of CXCL11 through releasing HMGB1, thereby improving the infiltration of endogenous lymphocytes and CAR-T cells and strengthening anti-tumor responses in patients with lung cancer [53].

CXCR1/CXCR2

Recently, researchers took exceptional interest in C-X-C chemokine receptor (CXCR) 1 and CXCR2, whose ligands are predominantly expressed by various tumors to shape hostile TME. Engineering CAR-T cells with CXCR1 or CXCR2 remarkably augmented tumor infiltration. Moreover, this novel CAR-T cells elicited sustained tumor recession and long-lasting immunologic memory in various tumor models such as glioblastoma, ovarian and pancreatic cancers, even in advanced cancers [48, 49]. Similarly, SX-682, the inhibitor of CXCR1 and CXCR2, could block the trafficking of CXCR2+ myeloid-derived suppressor cells (MDSC), subsequently enhancing the infiltration of adoptive and endogenous lymphocytes, producing much stronger anti-tumor responses in HCC [50].

IL-7 and CCL19

Previous studies demonstrated that T zone fibroblastic reticular cells are implicated in T-cell homeostasis by secreting IL-7 and CCL19 [54, 55]. Keishi Adachi *et al* developed novel CAR-T cells incorporating IL-7 and CCL19 (17X19 CAR-T) to mimic T-zone reticular cells. IL-7 downregulated PD1 expression, promoting CAR T-cell survival and persistence. Besides, CCL19-CCR7 interaction increased tumor infiltration of adoptive and endogenous immune cells (T cells and DCs) [55], thereby improving anti-tumor effects. In the different tumor-bearing mice, 7X19 CAR-T therapies all elicited complete tumor regression and prolonged survival of mice without tumor relapse. Moreover, the 1/4 dose of 7X19 CAR-T cells produced greater or at least comparable anti-tumor efficacy than traditional CAR-T therapy [56]. Numerous cen-

Table 2. Summary of using chemokines and chemokine receptors to facilitate CAR T-cell migration and infiltration

Related cytokines	Application	Mechanism	Diseases	Clinical trials	References
CCL17/CCL22/CCR4	Co-express CCR4	Increase T-cell trafficking and infiltration	Hodgkin lymphoma	NCT03602157	[45]
CCL2/CCR2b	Co-express CCR2b	Increase T-cell trafficking and infiltration	Malignant pleural mesotheliomas	-	[46, 47]
			Neuroblastoma		
CXCL13/CXCR5	Co-express CXCR5	Increase T-cell trafficking and infiltration	Non-small cell lung cancer	NCT04153799	-
Ligands/CXCR1/CXCR2	Co-express CXCR1 or CXCR2	Increase T-cell trafficking and infiltration	Glioblastoma	-	[48, 49]
		Produce long-lasting immunologic memory	Ovarian cancer		
			Pancreatic cancer		
			Hepatocellular carcinoma		
	Inhibitor SX-682	Block trafficking of CXCR2+ MDSC		-	[50]
CXCL10/CXCR3	Inhibitor Sitagliptin	Preserve CXCL10	Hepatocellular carcinoma	NCT02650427	[52]
		Enhance migration of lymphocytes			
CXCL11	Docetaxel	Increase the secretion of CXCL11	Non-small cell lung cancer	-	[53]
		Improve infiltration of lymphocytes			
IL-7+CCL19	Co-expression	Enhance T-cell proliferation and persistence	B-cell lymphoma	NCT03929107	[56]
		Increase T/DC cells trafficking and infiltration	Multiple myeloma	NCT03778346	
		Induce more memory cells	Nectin4+ solid tumor	NCT03932565	

Clinical trial-related information were mainly collected from ClinicalTrials.gov. Abbreviations: CCL, C-C chemokine ligand; CCR, C-C chemokine receptor; CXCL, C-X-C chemokine ligand; CXCR, C-X-C chemokine receptor; MDSC, myeloid-derived suppressor cells; DC, dendritic cells.

Figure 3. Targeting immunosuppressive molecules in the TME to promote the CAR-T therapy. CAR-T cells equipped with dnTGFβRII or knocking out TGFβRII in CAR-T cells with CRISPR/Cas9 technology strengthened anti-tumor efficacy due to insensitive to TGFβ. Besides, the inhibitory endodomain of IL-4 receptor can be replaced by activator receptor including IL-2/IL-15, IL-7 and IL-21 to transduce pro-survival signals for lymphocytes.

main aspects, which can directly promote cancer progression and indirectly forming suppressive milieu, to restrict CAR T-cell proliferation and cytotoxic function. However, modified cytokine receptors, including dominant negative receptor (DNR) and inverted cytokine receptor (ICR), enable CAR-T cells to antagonize aforementioned repressive factors, thus exerting superior anti-tumor effects, the main point of this part (**Figure 3**; **Table 3**).

TGFβ

TGFβ is rich in a variety of carcinomas and favors advanced tumor progression in many ways, including epithelial-to-mesenchymal transition, angiogenesis and metastasis (reviewed in [59]). Besides, TGFβ participates in the formation of the unfavorable TME, which markedly suppresses immune surveillance by inhibiting T-cell proliferation, downregulating the critical proteins of CTLs (perforin, granzymes and cytotoxins) and generating Tregs (reviewed in [57]).

TGFβ receptor type II (TGFβRII) lacked intracellular domain for signal transduction [60], and thus T cells engineered to express dominant-negative TGFβRII (dnTGFβRII) were insensitive to TGFβ [61]. Multiple centers exhibited that CAR-T cells equipped with dnTGFβRII could promote prostate tumor eradication [62-64]. In addition to dnTGFβRII, utilizing CRISPR/Cas9 technology to knock out endogenous TGFβRII of CAR-T cells also produced comparable anti-tumor effects. Upon re-exposure to the same antigen, the number of Tcm and effector memory T (Tm) cells were sharply elevated, recalling robust and long-term memory responses [65].

Given durable tumor regression in preclinical models, dnTGFβRII was quickly put into clinical practice for the treatment of various tumors (NCT00368082, NCT02065362, NCT008899-

ters have undertaken related clinical trials to assess the safety and effectiveness of 17X19 CAR-T therapy for patients with r/r B cell lymphoma (NCT03929107), multiple myeloma (NCT03778346) and other malignant solid tumors (NCT03932565).

Immunosuppressive molecules

What CAR-T cells confront after trafficking into the tumors is multifarious and intricate inhibitory factors in the TME. The TME consists of tumor cells and various components, including fibroblasts, endothelial cells, mesenchymal cells, suppressive immune cells, along with extracellular matrix and inflammatory mediators they secrete, which not only promote malignant growth of tumors, but also impair anti-tumor immunity in different ways [7]. Soluble inhibitory molecules in the TME, like IL-4, IL-10, transforming growth factor-β (TGFβ) [57] and prostaglandin E2 (PGE2) [58], are one of the

Table 3. Summary of targeting immunosuppressive molecules in the TME to promote the CAR-T therapy

Related cytokines	Application	Mechanism	Diseases	Clinical trials	References
TGFβ	TGFβ antibody	Block TGFβ	Hepatocellular carcinoma	NCT03198546	-
	DnTGFβRII	Insensitive to TGFβ	Melanoma	NCT03089203	[61-64]
			Prostate cancer	NCT04227275	
			EBV+ lymphoma	NCT00368082	
			Nasopharyngeal carcinoma	NCT02065362	
			Her2+ malignancy	NCT00889954	
	Knock out TGFβR2	Insensitive to TGFβ	Lung cancer	-	[65]
		Increase Tcm and Tem phenotype	Pancreatic carcinoma		
IL-4	T4 immunotherapy	Antagonize inhibition of IL-4	Epithelial ovarian cancer	NCT01818323	[68-71]
		Produce crucial growth stimulation	Malignant mesothelioma		
			Head and neck cancer		
	4/7 ICR	Antagonize inhibition of IL-4	Pancreatic cancer	-	[67, 72, 73]
		Preserve Th1 phenotype	Breast cancer		
		Produce long-term persistence	EBV+ lymphoblastoma		
	4/21 ICR	Antagonize inhibition of IL-4	Hepatocellular carcinoma	-	[74]
		Promote Th17-like polarization			

Clinical trial-related information were mainly collected from ClinicalTrials.gov. Abbreviations: TGFβ, transforming growth factor-β; DnTGFβRII, dominant-negative TGFβ recepter II; Tcm, central memory T cells; Tem, effector memory T cells; ICR, inverted cytokine receptor.

Figure 4. Mechanisms for enhancing CAR-T effects by using pro-inflammatory cytokines. CAR-T cells equipped with pro-inflammatory cytokines like IL-12, IL-18 not only form acute inflammatory microenvironment suitable for immunity, but also reactivate endogenous lymphocytes to exert anti-tumor responses.

54, NCT03089203, NCT04227275). In Hodgkin lymphoma, T cells armed with dnTGFβRII expanded well and persisted up to 4 years after infusion. Four of the seven evaluable patients achieved clinical responses and two patients were in remission for more than four years, including one who achieved only partial response (PR) after conventional CAR-T therapy [66]. Besides, dual-specific CAR-T cells targeting both tumor antigen and soluble TGFβ (GPC3/TGFβ-CART) have also been tried to treat HCC (NCT03198546).

IL-4

IL-4 is also a soluble inhibitory molecule commonly found in various cancer milieu. It can promote expansion and invasion of cancer cells, support M2 macrophage differentiation and upregulate secretion of Th2-polarized cytokines, thereby promoting tumor proliferation and inhibiting immune cells function [67].

Inverted cytokine receptor (ICR) that enables suppressive factors to deliver activation signals also shows good prospect of application. The early attempt was "T4 immunotherapy", in which IL-4Rα was fused with endodomain β-chain shared by IL-2R and IL-15R (4αβ), thereby allowing IL-4-mediated CAR T-cell proliferation rather than inhibition [68]. Introducing 4αβ to CAR-T cells had great survival advantages in the IL-4-rich TME with robust anti-tumor effects on epithelial ovarian cancer and malignant mesothelioma [69, 70]. And a study has already been registered as a clinical trial for head and neck cancer (NCT01818323) [71]. Apart from 4αβ, IL-4Rα can also link to the IL-7R intracellular segment (4/7 ICR). Researches showed that CAR-T cells incorporating 4/7 ICR retained Th1 phenotype with long-term persistence and durable tumor control in pre-clinical models of lymphoblastoma [67], pancreatic [72] and breast cancers [73]. 4/21 ICR worked in a similar way, but 4/21 ICR induced STAT3 phosphorylation and promoted Th17-like polarization [74], which is a less differentiated subset, and is closely correlated with anti-tumor responses involving CAR-T therapy [75].

Pro-inflammatory cytokines

Given their ability of directed migration to tumor sites, CAR-T cells can serve as a targeting vehicle to transfer immune-modulating transgenic protein ("payload") and discharge it upon CAR engagement with tumor antigens. The most common and powerful payloads are versatile pro-inflammatory cytokines, which can recruit endogenous immune cells to elicit anti-tumor attack against the cancer cells invisible to CAR-T cells (**Figure 4**; **Table 4**). This strategy is represented by T cells redirected for universal cytokine killing (TRUCK) [76, 77]. Also, TRUCK cells are locally delivered, thereby overcoming the systemic toxicity of exogenous administra-

Table 4. Summary of enhancing CAR-T effects by using pro-inflammatory cytokines

Related cytokines	Application	Mechanism	Diseases	Clinical trials	References
IL-12	Co-expression	Enhance T-cell omnifarious performance	Hodgkin lymphoma	NCT01236573	[79-82, 84, 87-89]
		Trigger programmatic changes in the TME	Metastatic melanoma	NCT02498912	
		Recruit and activate endogenous immunity	Ovarian cancer	NCT03542799	
			Colorectal tumor	NCT01457131	
			Hepatocellular carcinoma		
			NY-ESO-1+ metastatic cancer		
IL-18	Co-expression	Augment T-cell proliferation and persistence	CD19+ malignancies	-	[90-94]
		Transform Th1 phenotype	Pancreatic tumor		
		Regulate innate immune cells and TME	Lung tumor		
		Induce FoxO1^{low} T-bet^{high} T-cell phenotype	Ovarian cancer		
			Breast cancer		

Clinical trial-related information were mainly collected from ClinicalTrials.gov. Abbreviations: TME, tumor microenvironme.

tion, and release cytokines upon CAR stimulation, avoiding repetitive drug application [78]. Clinical trials showed remarkable efficacy and great prospects of future application. The expression of cytokines is either constitutive or inducible according to distinct promoters.

IL-12

IL-12 is the paradigmatic and impressive cytokine for "TRUCKs" (reviewed in [77]), which promotes tumor recession by at least three mechanisms, including prolonging CAR-T cells survival and persistence [79, 80], inverting inhibitory or chronic inflammatory TME into acute inflammation suitable for immunity [80-83], recruiting and activating innate immune cells to cause a second wave of anti-tumor responses [84-86].

The first application chose EBV-specific CTLs for the treatment of HL. The armored CTLs secreting IL-12 were insensitive to the suppressive environment, persisting longer and mounting stronger anti-tumor responses [82]. Later pre-clinical models of ovarian cancer [79, 80], colorectal tumor [84], HCC [81] and so on [87], whether immunodeficiency or immunocompetence, whether constitutive or inducible expression, IL-12 secreting CAR-T cells could produce sustained tumor eradication. Consequently, the first-in-human clinical trial was initially conducted in metastatic melanoma (NCT01236573). Results showed that TILs transduced with IL-12 achieved comparable effects at a dose 10- to 100-fold lower than conventional TILs. Even though therapeutic effects were transient owing to the short persistence of TILs *in vivo* and unexpected toxicity occurred when given at higher doses, this innovative method still showed a promise of future application [88]. To date, more and more centers have registered clinical trials aimed to evaluate the safety and effectiveness of CAR-T cells co-expressing IL-12 (NCT02498912, NCT03542799, NCT01457131) [89].

IL-18

IL-18 is another pro-inflammatory cytokine, possessing many effects comparable to IL-12 [90]. Compared with IL-12, CAR-T therapy integrating IL-18 can reduce oedema-like toxicity due to lower level of IFN-γ and TNFα, and increase TILs by decreasing macrophage recruitment, thus producing safer and higher anti-tumor activities [91]. It is known that CAR-T cells with acute inflammatory and less differentiated signatures are believed to be superior in triggering long-time anti-tumor responses. And IL-18 can induce FoxO1^{low} T-bet^{high} T-cell phenotype, which exactly fulfills the requirements [92]. Subsequent investigations further verified the safety and robust anti-tumor effects of IL-18-secreting CAR-T therapy in many malignancies [92-94].

Risks and challenges

However, the universal use of CAR-T cells armed with cytokines still has a long way to go even if the impressive results indicate a high potential for future application. The production of novel CAR-T cells entails introduction of two vector constructs for CAR expression and cytokine secretion, which might increase the risk of insertional mutagenesis and integration of viral vectors [95]. And two products, the CAR and cytokines, further complicate the definition of cellular kinetics and clinical pharmacology [96]. Besides, transgenic CAR-T cells might aggravate adverse effects of cellular therapy such as cytokine release syndrome (CRS) and "on target off tumor" toxicity, because of the additional release of pro-inflammatory cytokines, resulting in more severe tissue damage and local reaction. Another safety concern is the background cytokines release independent of CAR stimulation due to the "leakage" of promoters. Currently, the nuclear factor of activated T-cell (NFAT) promoter is mostly applied for inducible cytokines secretion, which is also triggered by normal TCR engagement, and exceeding physiological levels may produce "off target off tumor" toxicity in healthy tissues [88]. What's more, constitutive expression of pro-survival cytokines or continuous activation of signaling pathways may induce autonomous proliferation, and the risk of malignant transformation cannot be entirely ruled out [97].

To overcome these obstacles, a variety of strategies for improving safety have been proposed. One study worked out an "all-in-one" vector system, which utilized a modified NFATsyn promoter to combine constitutive CAR expression with inducible cytokine secretion through only one vector, thereby simplifying the construct of CAR-T and reducing insertional mutagenesis [95]. Regulatable switches are appropriate

alternatives to reduce the toxicity of excessive release of cytokines and potential autonomous proliferation, including suicide genes, synNotch receptors, switch CAR, among others (reviewed in [98]). Considering the background expression of cytokines, a well-designed dose-escalation plan is required in the clinical trials for determining the maximum tolerated dose (MTD), whereas exploring strictly CAR-dependent promoters shows more advantages in the long run.

Conclusions and perspective

Use of CAR-T cells has revolutionized cancer treatment, but tapping the full capacity of CAR-T therapy requires further scientific exploration [99]. Arming CAR-T cells with diverse cytokines can enhance CAR T-cell proliferation and persistence, improve trafficking and infiltration of CAR-T cells, antagonize inhibitory molecules in the TME and reactivate innate immunity, thus strengthening anti-tumor responses and inducing long-term cancer regression. Besides, preclinical models and trials with "armored" CAR-T therapy also exhibited impressive effects. CAR-T cells incorporating cytokines not only achieved comparable anti-tumor results with 10- to 100-fold lower doses [88], but also expanded well and persisted for over four years after infusion [66]. Moreover, TRUCK cells can reactivate endogenous immunity, thus initiating a second attack toward those antigen-loss tumor cells which might lead to antigen escape.

Identifying appropriate cytokines remains a challenge, and the key factor is the specific clinical response of different tumors. If the CAR expression is rarely detected within a few weeks after reinfusing into patients, combination use with the aforementioned γc cytokines should be considered [100]. In dealing with "cold" tumors, where immune cells have no or little infiltration [41], co-expression of tumor-related chemokine receptors or modification of inhibitory receptors are powerful tools to improve prognosis. Also, the high frequency of targeted antigen-negative relapse [101] suggests that the therapy should be used in combination with IL-12 or IL-18 to mobilize endogenous immune cells. Definitively, high-throughput proteomics of serum from patients or cytokine screen for specific phenotype CAR-T cells is critical to the discovery of novel and effective cytokines [92]. Additionally, cytokines with different functions can work synergistically. For example, CAR-T cells integrating IL-15 and IL-21 exhibited enhanced proliferative capacity, with more Tscm and Tcm cells populations [31]. 7X19 CAR-T cells co-expressing two functional cytokines (IL-7 and CCL19) can enhance proliferation and infiltration and recruit endogenous immune cells, and are a promising alternative [56]. Recent study showed that 7X21 CAR-T cells also had similar synergistic effects [102]. However, not all these cytokines are effective in all kinds of cancers due to tumor heterogeneity. It is critical to determine the appropriate cytokines or cytokine receptors in CAR-T therapy on the basis of the signature of cytokines secreted by distinct tumors. The receptors include "matched" chemokine receptors to enhance migration and modified receptors, such as ICR or DNR, to antagonize immunosuppressive molecules. Other survival-promoting cytokines target CAR-T cells themselves, and can be applied to various tumors to improve CAR-T efficacy. As mentioned above, co-expression of certain γc cytokines could enhance the expansion and persistence of CAR-T cells *in vivo* by activating JAK/STAT3 or STAT5 pathway regardless of tumor types, thus improving the efficacy of CAR-T therapy.

This review outlines CAR-T therapy coupled with various cytokines, which exerts promising anti-tumor effects and potential for clinical application even if some challenges remain. Undoubtedly, further researches will further improve the efficacy and safety of CAR-T cell therapy.

Acknowledgements

Disclosure of conflict of interest

None.

Address correspondence to: Jianfeng Zhou and Hui Luo, Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology & Immunotherapy Research Center for Hematologic Diseases, Wuhan 430030, Hubei, P. R. China. Tel: +86-27-83665007; Fax: +86-

27-83662680; E-mail: jfzhou@tjh.tjmu.edu.cn (JFZ);
luohui_tjh@163.com (HL)

References

[1] Hoos A. Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations. Nat Rev Drug Discov 2016; 15: 235-247.

[2] Porter DL, Levine BL, Kalos M, Bagg A and June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011; 365: 725-733.

[3] Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL and June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013; 368: 1509-1518.

[4] Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng ZH, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL and Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371: 1507-1517.

[5] Park JH, Riviere I, Gonen M, Wang XY, Senechal B, Curran KJ, Sauter C, Wang YZ, Santomasso B, Mead E, Roshal M, Maslak P, Davila M, Brentjens RJ and Sadelain M. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N Engl J Med 2018; 378: 449-459.

[6] Brentjens RJ, Davila ML, Riviere I, Park J, Wang XY, Cowell LG, Bartido S, Stefanski J, Taylor C, Olszewska M, Borquez-Ojeda O, Qu JR, Wasielewska T, He Q, Bernal Y, Rijo IV, Hedvat C, Kobos R, Curran K, Steinherz P, Jurcic J, Rosenblat T, Maslak P, Frattini M and Sadelain M. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013; 5: 177ra38.

[7] Turley SJ, Cremasco V and Astarita JL. Immunological hallmarks of stromal cells in the tumor microenvironment. Nat Rev Immun 2015; 15: 669-682.

[8] Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA and Grupp SA. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. New N Engl J Med 2018; 378: 439-448.

[9] Brudno JN and Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood 2016; 127: 3321-3330.

[10] Lin JK, Lerman BJ, Barnes JI, Boursiquot BC, Tan YJ, Robinson AQL, Davis KL, Owens DK and Goldhaber-Fiebert JD. Cost effectiveness of chimeric antigen receptor T-cell therapy in relapsed or refractory pediatric B-cell acute lymphoblastic leukemia. J Clin Oncol 2018; JCO2018790642.

[11] Yamane H and Paul WE. Cytokines of the gamma(c) family control CD4(+) T cell differentiation and function. Nat Immunol 2012; 13: 1037-1044.

[12] Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, Timmerman JM, Stiff PJ, Friedberg JW, Flinn IW, Goy A, Hill BT, Smith MR, Deol A, Farooq U, McSweeney P, Munoz J, Avivi I, Castro JE, Westin JR, Chavez JC, Ghobadi A, Komanduri KV, Levy R, Jacobsen ED, Witzig TE, Reagan P, Bot A, Rossi J, Navale L, Jiang Y, Aycock J, Elias M, Chang D, Wiezorek J and Go WY. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 2017; 377: 2531-2544.

[13] Jensen MC, Popplewell L, Cooper LJ, DiGiusto D, Kalos M, Ostberg JR and Forman SJ. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CDI9-specific chimeric antigen receptor redirected T cells in humans. Biol Blood Marrow Transplant 2010; 16: 1245-1256.

[14] Rochman Y, Spolski R and Leonard WJ. New insights into the regulation of T cells by gamma(c) family cytokines. Nat Rev Immunol 2009; 9: 480-490.

[15] Lenardo MJ. Interleukin-2 programs mouse alpha-beta-lymphocytes-T for apoptosis. Nature 1991; 353: 858-861.

[16] Kaartinen T, Luostarinen A, Maliniemi P, Keto J, Arvas M, Belt H, Koponen J, Loskog A, Mustjoki S, Porkka K, Yla-Herttuala S and Korhonen M. Low interleukin-2 concentration favors generation of early memory T cells over effector phenotypes during chimeric antigen receptor T-cell expansion. Cytotherapy 2017; 19: 689-702.

[17] Till BG, Jensen MC, Wang JJ, Chen EY, Wood BL, Greisman HA, Qian XJ, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR and Press OW. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood 2008; 112: 2261-2271.

[18] Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR, Morton KE,

Laurencot CM, Steinberg SM, White DE and Dudley ME. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 2011; 17: 4550-4557.

[19] Alwan LM, Grossmann K, Sageser D, Van Atta J, Agarwal N and Gilreath JA. Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Target Oncol 2014; 9: 63-71.

[20] Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC and Riddell SR. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood 2009; 114: 2417-2426.

[21] Sabatino M, Hu J, Sommariva M, Gautam S, Fellowes V, Hocker JD, Dougherty S, Qin H, Klebanoff CA, Fry TJ, Gress RE, Kochenderfer JN, Stroncek DF, Ji Y and Gattinoni L. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 2016; 128: 519-528.

[22] Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, Rooney CM, Savoldo B and Dotti G. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014; 123: 3750-3759.

[23] Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo CF, Aguilar B, Qi Y, Ann DK, Starr R, Urak R, Wang X, Forman SJ and Brown CE. IL15 enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res 2019; 7: 759-772.

[24] Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ and Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood 2008; 111: 5326-5333.

[25] Singh H, Figliola MJ, Dawson MJ, Huls H, Olivares S and Switzer K. Reprogramming CD19-specific T cells with IL-21 signaling can improve adoptive immunotherapy of B-lineage malignancies (vol 71, pg 3516, 2011). Cancer Res 2011; 71: 4734-4734.

[26] Xu X, Gnanaprakasam JNR, Sherman J and Wang R. A metabolism toolbox for CAR T therapy. Front Oncol 2019; 9: 322.

[27] Tagaya Y, Bamford RN, DeFilippis AP and Waldmann TA. IL-15: A pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity 1996; 4: 329-336.

[28] Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, Heslop HE, Rooney CM, Brenner MK and Dotti G. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia 2010; 24: 1160-1170.

[29] Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV and Gottschalk S. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol Res 2017; 5: 571-581.

[30] Chen Y, Sun C, Landoni E, Metelitsa L, Dotti G and Savoldo B. Eradication of neuroblastoma by T cells redirected with an optimized GD2-specific chimeric antigen receptor and interleukin-15. Clin Cancer Res 2019; 25: 2915-2924.

[31] Batra SA, Rathi P, Guo L, Courtney AN, Fleurence J, Balzeau J, Shaik RS, Nguyen TP, Wu MF, Bulsara S, Mamonkin M, Metelitsa LS and Heczey A. Glypican-3-specific CAR T cells coexpressing IL15 and IL21 have superior expansion and antitumor activity against hepatocellular carcinoma. Cancer Immunol Res 2020; 8: 309-320.

[32] Hurton LV, Singh H, Najjar AM, Switzer KC, Mi T, Maiti S, Olivares S, Rabinovich B, Huls H, Forget MA, Datar V, Kebriaei P, Lee DA, Champlin RE and Cooper LJ. Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells. Proc Natl Acad Sci U S A 2016; 113: E7788-E7797.

[33] Seddiki N, Santner-Nanan B, Martinson J, Zaunders J, Sasson S, Landay A, Solomon M, Selby W, Alexander SI, Nanan R, Kelleher A and Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 1693-1700.

[34] Perna SK, Pagliara D, Mahendravada A, Liu H, Brenner MK, Savoldo B and Dotti G. Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition. Clin Cancer Res 2014; 20: 131-139.

[35] Vera JF, Hoyos V, Savoldo B, Quintarelli C, Attianese GMPG, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, Brenner MK and Dotti G. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009; 17: 880-888.

[36] Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, Yi Z, Sauer T, Liu D, Parihar R, Castillo P, Liu H, Brenner MK, Metelitsa LS, Gottschalk S and Rooney CM. Constitutive signaling from an engineered IL7 receptor promotes durable tumor elimination by tumor-redirected T cells. Cancer Discov 2017; 7: 1238-1247.

[37] Zhao Z, Li Y, Liu W and Li X. Engineered IL-7 receptor enhances the therapeutic effect of AXL-CAR-T cells on triple-negative breast cancer. Biomed Res Int 2020; 2020: 4795171.

[38] Kagoya Y, Tanaka S, Guo T, Anczurowski M, Wang CH, Saso K, Butler MO, Minden MD and Hirano N. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects. Nat Med 2018; 24: 352-359.

[39] Oppmann B, Lesley R, Blom B, Timans JC, Xu YM, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu MR, Gorman D, Wagner J, Zurawski S, Liu YJ, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF and Kastelein RA. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000; 13: 715-725.

[40] Ma X, Shou P, Smith C, Chen Y, Du H, Sun C, Porterfield Kren N, Michaud D, Ahn S, Vincent B, Savoldo B, Pylayeva-Gupta Y, Zhang S, Dotti G and Xu Y. Interleukin-23 engineering improves CAR T cell function in solid tumors. Nat Biotechnol 2020; 38: 448-459.

[41] Galon J and Bruni D. Approaches to treat immune hot, altered and cold tumors with combination immunotherapies. Nat Rev Drug Discov 2019; 18: 197-218.

[42] Nagarsheth N, Wicha MS and Zou WP. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017; 17: 559-572.

[43] Ishida T, Ishii T, Inagaki A, Yano H, Komatsu H, Iida S, Inagaki H and Ueda R. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66: 5716-5722.

[44] van den Berg A, Visser L and Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells - A possible explanation for the characteristic T-cell infiltrate in Hodgkin's lymphoma. Am J Pathol 1999; 154: 1685-1691.

[45] Di Stasi A, De Angelis B, Rooney CM, Zhang L, Mahendravada A, Foster AE, Heslop HE, Brenner MK, Dotti G and Savoldo B. T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model. Blood 2009; 113: 6392-6402.

[46] Craddock JA, Lu A, Bear A, Pule M, Brenner MK, Rooney CM and Foster AE. Enhanced tumor trafficking of GD2 chimeric antigen receptor T cells by expression of the chemokine receptor CCR2b. J Immunother 2010; 33: 780-788.

[47] Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH and Albelda SM. Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor. Clin Cancer Res 2011; 17: 4719-4730.

[48] Jin L, Tao H, Karachi A, Long Y, Hou AY, Na M, Dyson KA, Grippin AJ, Deleyrolle LP, Zhang W, Rajon DA, Wang QJ, Yang JC, Kresak JL, Sayour EJ, Rahman M, Bova FJ, Lin Z, Mitchell DA and Huang J. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors. Nat Commun 2019; 10: 4016.

[49] Liu G, Rui W, Zheng H, Huang D, Yu F, Zhang Y, Dong J, Zhao X and Lin X. CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma. Eur J Immunol 2020; 50: 712-724.

[50] Sun L, Clavijo PE, Robbins Y, Patel P, Friedman J, Greene S, Das R, Silvin C, Van Waes C, Horn LA, Schlom J, Palena C, Maeda D, Zebala J and Allen CT. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy. JCI Insight 2019; 4: e126853.

[51] Lambeir AM, Proost P, Durinx C, Bal G, Senten K, Augustyns K, Scharpe S, Van Damme J and De Meester I. Kinetic investigation of chemokine truncation by CD26/dipeptidyl peptidase IV reveals a striking selectivity within the chemokine family. J Biol Chem 2001; 276: 29839-29845.

[52] Barreira da Silva R, Laird ME, Yatim N, Fiette L, Ingersoll MA and Albert ML. Dipeptidyl-peptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy. Nat Immunol 2015; 16: 850-858.

[53] Gao Q, Wang S, Chen X, Cheng S, Zhang Z, Li F, Huang L, Yang Y, Zhou B, Yue D, Wang D, Cao L, Maimela NR, Zhang B, Yu J, Wang L and Zhang Y. Cancer-cell-secreted CXCL11 promoted CD8(+) T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC. J Immunother Cancer 2019; 7: 42.

[54] Link A, Vogt TK, Favre S, Britschgi MR, Acha-Orbea H, Hinz B, Cyster JG and Luther SA. Fibroblastic reticular cells in lymph nodes regulate the homeostasis of naive T cells. Nat Immunol 2007; 8: 1255-1265.

[55] Luther SA, Bidgol A, Hargreaves DC, Schmidt A, Xu Y, Paniyadi J, Matloubian M and Cyster JG. Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis. J Immunol 2002; 169: 424-433.

[56] Adachi K, Kano Y, Nagai T, Okuyama N, Sakoda Y and Tamada K. IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor. Nat Biotechnol 2018; 36: 346-351.

[57] Yang L, Pang YL and Moses HL. TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol 2010; 31: 220-227.

[58] Mulligan JK, Day TA, Gillespie MB, Rosenzweig SA and Young MRI. Secretion of vascular endothelial growth factor by oral squamous cell carcinoma cells skews endothelial cells to suppress T-cell functions. Human Immunol 2009; 70: 375-382.

[59] Massague J. TGFbeta in cancer. Cell 2008; 134: 215-230.

[60] Ebner R, Chen RH, Shum L, Lawler S, Zioncheck TF, Lee A, Lopez AR and Derynck R. Cloning of a type I TGF-beta receptor and its effect on TGF-beta binding to the type II receptor. Science 1993; 260: 1344-1348.

[61] Gorelik L and Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001; 7: 1118-1122.

[62] Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y and June CH. Dominant-negative TGF-beta receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol Ther 2018; 26: 1855-1866.

[63] Zhang Q, Helfand BT, Carneiro BA, Qin W, Yang XJ, Lee C, Zhang W, Giles FJ, Cristofanilli M and Kuzel TM. Efficacy against human prostate cancer by prostate-specific membrane antigen-specific, transforming growth factor-beta insensitive genetically targeted CD8(+) T-cells derived from patients with metastatic castrate-resistant disease. Eur Urol 2018; 73: 648-652.

[64] Zhang L, Yu Z, Muranski P, Palmer DC, Restifo NP, Rosenberg SA and Morgan RA. Inhibition of TGF-β signaling in genetically engineered tumor antigen-reactive T cells significantly enhances tumor treatment efficacy. Gene Therapy 2012; 20: 575-580.

[65] Tang N, Cheng C, Zhang X, Qiao M, Li N, Mu W, Wei XF, Han W and Wang H. TGFbeta inhibition via CRISPR promotes the long-term efficacy of CAR-T cells against solid tumors. JCI Insight 2020; 5: e133977.

[66] Bollard CM, Tripic T, Cruz CR, Dotti G, Gottschalk S, Torrano V, Dakhova O, Carrum G, Ramos CA, Liu H, Wu MF, Marcogliese AN, Barese C, Zu YL, Lee DY, O'Connor O, Gee AP, Brenner MK, Heslop HE and Rooney CM. Tumor-specific T-cells engineered to overcome tumor immune evasion induce clinical responses in patients with relapsed hodgkin lymphoma. J Clin Oncol 2018; 36: 1128-1139.

[67] Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, Brenner MK and Vera JF. Reversal of tumor immune in-

hibition using a chimeric cytokine receptor. Mol Ther 2014; 22: 1211-1220.

[68] Wilkie S, Burbridge SE, Chiapero-Stanke L, Pereira AC, Cleary S, van der Stegen SJ, Spicer JF, Davies DM and Maher J. Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4. J Biol Chem 2010; 285: 25538-25544.

[69] Parente-Pereira AC, Whilding LM, Brewig N, van der Stegen SJ, Davies DM, Wilkie S, van Schalkwyk MC, Ghaem-Maghami S and Maher J. Synergistic chemoimmunotherapy of epithelial ovarian cancer using ErbB-retargeted T cells combined with carboplatin. J Immunol 2013; 191: 2437-2445.

[70] Klampatsa A, Achkova DY, Davies DM, Parente-Pereira AC, Woodman N, Rosekilly J, Osborne G, Thayaparan T, Bille A, Sheaf M, Spicer JF, King J and Maher J. Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells. Cancer Lett 2017; 393: 52-59.

[71] van Schalkwyk MC, Papa SE, Jeannon JP, Guerrero Urbano T, Spicer JF and Maher J. Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer. Hum Gene Ther Clin Dev 2013; 24: 134-142.

[72] Mohammed S, Sukumaran S, Bajgain P, Watanabe N, Heslop HE, Rooney CM, Brenner MK, Fisher WE, Leen AM and Vera JF. Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 2017; 25: 249-258.

[73] Bajgain P, Tawinwung S, D'Elia L, Sukumaran S, Watanabe N, Hoyos V, Lulla P, Brenner MK, Leen AM and Vera JF. CAR T cell therapy for breast cancer: harnessing the tumor milieu to drive T cell activation. J Immunother Cancer 2018; 6: 34.

[74] Wang Y, Jiang H, Luo H, Sun Y, Shi B, Sun R and Li Z. An IL-4/21 inverted cytokine receptor improving CAR-T cell potency in immunosuppressive solid-tumor microenvironment. Front Immunol 2019; 10: 1691.

[75] Guedan S, Chen X, Madar A, Carpenito C, McGettigan SE, Frigault MJ, Lee J, Posey AD, Scholler J, Scholler N, Bonneau R and June CH. ICOS-based chimeric antigen receptors program bipolar T(H)17/T(H)1 cells. Blood 2014; 124: 1070-1080.

[76] Chmielewski M, Hombach AA and Abken H. Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma. Immunol Rev 2014; 257: 83-90.

[77] Chmielewski M and Abken H. TRUCKs: the fourth generation of CARs. Expert Opinion on Biological Therapy 2015; 15: 1145-1154.

[78] Cohen J. Clinical-trials - Il-12 deaths - explanation and a puzzle. Science 1995; 270: 908-908.

[79] Koneru M, Purdon TJ, Spriggs D, Koneru S and Brentjens RJ. IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo. Oncoimmunology 2015; 4: e994446.

[80] Yeku OO, Purdon TJ, Koneru M, Spriggs D and Brentjens RJ. Armored CAR T cells enhance antitumor efficacy and overcome the tumor microenvironment. Sci Rep 2017; 7: 10541.

[81] Liu Y, Di S, Shi B, Zhang H, Wang Y, Wu X, Luo H, Wang H, Li Z and Jiang H. Armored inducible expression of IL-12 enhances antitumor activity of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J Immunol 2019; 203: 198-207.

[82] Wagner HJ, Bollard CM, Vigouroux S, Huls MH, Anderson R, Prentice HG, Brenner MK, Heslop HE and Rooney CM. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Therapy 2004; 11: 81-91.

[83] Kerkar SP, Goldszmid RS, Muranski P, Chinnasamy D, Yu Z, Reger RN, Leonardi AJ, Morgan RA, Wang E, Marincola FM, Trinchieri G, Rosenberg SA and Restifo NP. IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors. J Clin Invest 2011; 121: 4746-4757.

[84] Chmielewski M, Kopecky C, Hombach AA and Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res 2011; 71: 5697-5706.

[85] Kueberuwa G, Kalaitsidou M, Cheadle E, Hawkins RE and Gilham DE. CD19 CAR T cells expressing IL-12 eradicate lymphoma in fully lymphoreplete mice through induction of host immunity. Mol Ther Oncolytics 2018; 8: 41-51.

[86] Pegram HJ, Lee JC, Hayman EG, Imperato GH, Tedder TF, Sadelain M and Brentjens RJ. Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning. Blood 2012; 119: 4133-4141.

[87] Chinnasamy D, Yu Z, Kerkar SP, Zhang L, Morgan RA, Restifo NP and Rosenberg SA. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin Cancer Res 2012; 18: 1672-1683.

[88] Zhang L, Morgan RA, Beane JD, Zheng Z, Dudley ME, Kassim SH, Nahvi AV, Ngo LT, Sherry RM, Phan GQ, Hughes MS, Kammula US, Feldman SA, Toomey MA, Kerkar SP, Restifo NP, Yang JC and Rosenberg SA. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin Cancer Res 2015; 21: 2278-2288.

[89] Koneru M, O'Cearbhaill R, Pendharkar S, Spriggs DR and Brentjens RJ. A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer. J Transl Med 2015; 13: 102.

[90] Avanzi MP, Yeku O, Li X, Wijewarnasuriya DP, van Leeuwen DG, Cheung K, Park H, Purdon TJ, Daniyan AF, Spitzer MH and Brentjens RJ. Engineered tumor-targeted T cells mediate enhanced anti-tumor efficacy both directly and through activation of the endogenous immune system. Cell Rep 2018; 23: 2130-2141.

[91] Kunert A, Chmielewski M, Wijers R, Berrevoets C, Abken H and Debets R. Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors. Oncoimmunology 2017; 7: e1378842.

[92] Chmielewski M and Abken H. CAR T cells releasing IL-18 convert to T-Bet(high) FoxO1(low) effectors that exhibit augmented activity against advanced solid tumors. Cell Rep 2017; 21: 3205-3219.

[93] Hu B, Ren J, Luo Y, Keith B, Young RM, Scholler J, Zhao Y and June CH. Augmentation of antitumor immunity by human and mouse CAR T cells secreting IL-18. Cell Rep 2017; 20: 3025-3033.

[94] Huang Y, Li D, Zhang PF, Liu M, Liang X, Yang X, Jiang L, Zhang LF, Zhou WL, Su JH, Gong YL, Gou HF, Wei YQ and Wang W. IL-18R-dependent and independent pathways account for IL-18-enhanced antitumor ability of CAR-T cells. FASEB J 2019; 34: 1768-1782.

[95] Zimmermann K, Kuehle J, Dragon AC, Galla M, Kloth C, Rudek LS, Sandalcioglu IE, Neyazi B, Moritz T, Meyer J, Rossig C, Altvater B, Eiz-Vesper B, Morgan MA, Abken H and Schambach A. Design and characterization of an "all-in-one" lentiviral vector system combining constitutive anti-GD2 CAR expression and inducible cytokines. Cancers (Basel) 2020; 12: 375.

[96] Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA and Maude SL. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res 2018; 24: 6175-6184.

[97] Hsu C, Jones SA, Cohen CJ, Zheng ZL, Kerstann K, Zhou JH, Robbins PF, Peng PD, Shen XL, Gomes TJ, Dunbar CE, Munroe DJ, Stewart C, Cornetta K, Wangsa D, Ried T, Rosenberg SA and Morgan RA. Cytokine-independent growth and clonal expansion of a primary human CD8(+) T-cell clone following retroviral transduction with the IL-15 gene. Blood 2007; 109: 5168-5177.

[98] Yu SN, Yi M, Qin S and Wu KM. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer 2019; 18: 125.

[99] Schultz L and Mackall C. Driving CAR T cell translation forward. Sci Transl Med 2019; 11: eaaw2127.

[100] Dwyer CJ, Knochelmann HM, Smith AS, Wyatt MM, Rangel Rivera GO, Arhontoulis DC, Bartee E, Li Z, Rubinstein MP and Paulos CM. Fueling cancer immunotherapy with common gamma chain cytokines. Front Immunol 2019; 10: 263.

[101] Cheng J, Zhao L, Zhang Y, Qin Y, Guan Y, Zhang T, Liu C and Zhou J. Understanding the mechanisms of resistance to CAR T-cell therapy in malignancies. Front Oncol 2019; 9: 1237.

[102] Luo H, Su J, Sun R, Sun Y, Wang Y, Dong Y, Shi B, Jiang H and Li Z. Coexpression of IL7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion. Clin Cancer Res 2020; 26: 5494-5505.